Everything below concerns aggregation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
239Pu is a key fissile component in nuclear weapons, due to its ease of fission and availability. Encasing the bomb's plutonium pit in a tamper (a layer of dense material) decreases the critical mass by reflecting escaping neutrons back into the plutonium core. This reduces the critical mass from 16 kg to 10 kg, which is a sphere with a diameter of about 10 centimeters (4 in). This critical mass is about a third of that for uranium-235. The Fat Man plutonium bombs used explosive compression of plutonium to obtain significantly higher density than normal, combined with a central neutron source to begin the reaction and increase efficiency. Thus only 6 kg of plutonium was needed for an explosive yield equivalent to 20 kilotons of TNT. Hypothetically, as little as 4 kg of plutonium—and maybe even less—could be used to make a single atomic bomb using very sophisticated assembly designs.
The Mesopotamians seem to have had little interest in the natural world as such, preferring to study how the gods had ordered the universe. Animal physiology was studied for divination, including especially the anatomy of the liver, seen as an important organ in haruspicy. Animal behavior too was studied for divinatory purposes. Most information about the training and domestication of animals was probably transmitted orally, but one text dealing with the training of horses has survived. The ancient Mesopotamians had no distinction between "rational science" and magic. When a person became ill, doctors prescribed both magical formulas to be recited and medicinal treatments. The earliest medical prescriptions appear in Sumerian during the Third Dynasty of Ur (c. 2112 – c. 2004 BCE). The most extensive Babylonian medical text, however, is the Diagnostic Handbook written by the ummânū, or chief scholar, Esagil-kin-apli of Borsippa, during the reign of the Babylonian king Adad-apla-iddina (1069 – 1046 BCE). In East Semitic cultures, the main medicinal authority was an exorcist-healer known as an āšipu. The profession was passed down from father to son and was held in high regard. Of less frequent recourse was the asu, a healer who treated physical symptoms using remedies composed of herbs, animal products, and minerals, as well as potions, enemas, and ointments or poultices. These physicians, who could be either male or female, also dressed wounds, set limbs, and performed simple surgeries.
In the canonical androgen biosynthesis pathway, dihydrotestosterone (DHT) is synthesized irreversibly from testosterone (T) by the enzyme 5α-reductase, while T is synthesized from androstenediol (A5) or androstenedione (A4), which all are C19 steroids (androgens). The 5α-reduction of T occurs in various tissues including the genitals (penis, scrotum, clitoris, labia majora), prostate gland, skin, hair follicles, liver, and brain. Around 5 to 7% of T undergoes 5α-reduction into DHT in male adults. The liver is the main source of circulating DHT regardless of sex. Sex hormone-binding globulin (SHBH) transports the majority of circulating T to the cells of androgen target tissues, where it is then 5α-reduced to DHT. In adult males, approximately 70% of circulating DHT is produced by the peripheral conversion of T in non-gonadal tissues, with the remaining 30% directly secreted by the testes or adrenals; the prostate does not contribute to circulating DHT. In females, particularly from puberty onward, circulating DHT is almost entirely generated by peripheral conversion, resulting in levels that are only 3-10% of those found for T.
A blood smear, peripheral blood smear or blood film is a thin layer of blood smeared on a glass microscope slide and then stained in such a way as to allow the various blood cells to be examined microscopically . Blood smears are examined in the investigation of hematological (blood) disorders and are routinely employed to look for blood parasites, such as those of malaria and filariasis.
== Lignin == Lignin is a complex polyphenolic macromolecule composed mainly of beta-O4-aryl linkages. After cellulose, lignin is the second most abundant biopolymer and is one of the primary structural components of most plants. It contains subunits derived from p-coumaryl alcohol, coniferyl alcohol, and sinapyl alcohol, and is unusual among biomolecules in that it is racemic. The lack of optical activity is due to the polymerization of lignin which occurs via free radical coupling reactions in which there is no preference for either configuration at a chiral center.
Sources: en.wikipedia.org
In spite of lower subjective rating, that is, feeling that they performed worse, no clinically relevant differences were observed in the objective cognitive performance in a group of people treated for depression with sertraline for 1.5 years as compared to healthy controls. In children and adolescents taking sertraline for six weeks for anxiety disorders, 18 out of 20 measures of memory, attention, and alertness stayed unchanged. Divided attention was improved and verbal memory under interference conditions decreased marginally. Because of the large number of measures taken, it is possible that these changes were still due to chance. The unique effect of sertraline on dopaminergic neurotransmission may be related to these effects on cognition and vigilance. Sertraline has a low level of exposure of an infant through the breast milk and is recommended as the preferred option for the antidepressant therapy of breast-feeding mothers. However, there is 29–42% increase in congenital heart defects among children whose mothers were prescribed sertraline during pregnancy, with sertraline use in the first trimester associated with 2.7-fold increase in septal heart defects. Abrupt interruption of sertraline treatment may result in withdrawal or discontinuation syndrome. Dizziness, insomnia, anxiety, agitation, and irritability are common symptoms. It typically occurs within a few days from drug discontinuation and lasts a few weeks. The withdrawal symptoms for sertraline are less severe and frequent than for paroxetine, and more frequent than for fluoxetine.
=== Ownership and promotion === Knoll pharmaceuticals, originally founded in Germany in 1886, became a subsidiary of BASF (a German chemical company) in 1975. It was under their control when Vicoprofen was originally developed and approved. In March 2000, Knoll Pharmaceuticals and Abbott Laboratories, an American health care company, announced a co-promotion agreement for Vicoprofen, in which Abbott would promote Vicoprofen to its network of buyers, including physicians, hospitals, and surgical centers. In June 2002, Abbott Laboratories, paid $6.9 billion to acquire the entire Knoll pharmaceutical unit from BASF, including Vicoprofen.
No nihonium atoms were observed after chemical separation, implying an unexpectedly large retention of nihonium atoms on PTFE surfaces. This experimental result for the interaction limit of nihonium atoms with a PTFE surface (−ΔHPTFEads(Nh) > 45 kJ/mol) disagrees significantly with previous theory, which expected a lower value of 14.00 kJ/mol. This suggests that the nihonium species involved in the previous experiment was likely not elemental nihonium but rather nihonium hydroxide, and that high-temperature techniques such as vacuum chromatography would be necessary to further probe the behaviour of elemental nihonium. Bromine saturated with boron tribromide has been suggested as a carrier gas for experiments on nihonium chemistry; this oxidises nihonium's lighter congener thallium to thallium(III), providing an avenue to investigate the oxidation states of nihonium, similar to earlier experiments done on the bromides of group 5 elements, including the superheavy dubnium. A 2024 experiment at the GSI, producing 284Nh via the 243Am+48Ca reaction as daughter of 288Mc, studied the adsorption of nihonium and moscovium on SiO2 and gold surfaces. The adsorption enthalpy of nihonium on SiO2 was determined experimentally as −ΔHSiO2ads(Nh) = 58+8−3 kJ/mol (68% confidence interval). Nihonium was determined to be less reactive with the SiO2 surface than its lighter congener thallium, but more reactive than its closed-shell neighbours copernicium and flerovium. This arises because of the relativistic stabilisation of the 7p1/2 shell.
==== Other potential causes ==== Additional conditions that may present with similar clinical features include polymyalgia rheumatica, diabetic lumbosacral plexopathy, spinal stenosis, and non-inflammatory pain syndromes such as fibromyalgia.
=== Pharmacodynamics === Relative to other benzodiazepines, lorazepam is thought to have a high affinity for GABA receptors, which may also explain its marked amnesic effects. Its main pharmacological effects are the enhancement of the effects of the neurotransmitter GABA at the GABAA receptor. Benzodiazepines, such as lorazepam, enhance the effects of GABA at the GABAA receptor via increasing the frequency of opening of the chloride ion channel on the GABAA receptors; which results in the therapeutic actions of benzodiazepines. They, however, do not on their own activate the GABAA receptors but require the neurotransmitter GABA to be present. Thus, the effect of benzodiazepines is to enhance the effects of the neurotransmitter GABA. The magnitude and duration of lorazepam effects are dose-related, meaning larger doses have stronger and longer-lasting effects, because the brain has spare benzodiazepine drug receptor capacity, with single, clinical doses leading only to an occupancy of some 3% of the available receptors.
Sources: en.wikipedia.org
He wrote that: "They want to control our brotherhood... It is up to authentic Cuban Freemasons to prevent any of this from happening; once aware of the ever-growing influence State Security seeks to exert over our institution, we must not allow anyone likely linked to these agencies to assume the position." After arriving in the United States, Alfonso Vidal told reporters that former Grand Master Zamora Fernández, despite publicly appearing to stand against the injustice of the Cuban government, had privately apologized to the Communist Party. Alfonso Vidal said that at a special session of the Cuban Supreme Court of Masonic Justice, Zamora Fernández accused Master Mason Brian José Infante Machín from Logia Luz Caballero (English: Luz Caballero Lodge) of leading a conspiracy against the government, after which the Supreme Court expelled Infante Machín. Alfonso Vidal said that: "Zamora Fernández is weak-willed; his desire for recognition makes him vulnerable to State Security. I caught him crying the day he had to leave his post, and even now he hasn't come to terms with the fact that he's no longer the Grand Master. State Security takes advantage of all this; they seem to study your profile. They repeatedly emphasized that I was a noble and humble person, and that's how they approached me. Furthermore, officials from the Office of Religious Affairs speak very highly of him; in fact, they were confident that I would follow in Zamora's footsteps." He also called on the Freemasons of Cuba to elect Viñas Alonso as the Grand Master of Cuba.
== See also == List of ineffective cancer treatments List of topics characterized as pseudoscience Royal Commission on Animal Magnetism Royal touch Energy medicine Faith healing Laying on of hands Reiki Access Consciousness
The International Supply Chain Education Alliance (ISCEA) is a certifying body. Founded in 2003 and currently holding over 100,000 members, ISCEA has its World HQ office in Beachwood, OH, USA and regional offices in LATAM, EMEA and APAC. ISCEA is the governing body for the Ptak Prize. Besides Certified Supply Chain Manager (CSCM) certification, ISCEA has developed several professional certification programs that include: Certified Supply Chain Analyst (CSCA), Certified Lean Master (CLM), Certified RFID Supply Chain Manager (RFIDSCM), Certified Demand Driven Planner (CDDP), Certified HealthCare Supply Chain Analyst (CHSCA); and Certified Lean Six Sigma Yellow Belt (CLSSYB), Green Belt (CLSSGB) and Black Belt (CLSSBB).
== Characteristics == Various types of kōji are used, including yellow, black, and white. The kōji is stored for two to three days at 30°C under high humidity to allow A. oryzae to grow. In this process, the starch from cereals such as wheat, buckwheat or barley as well as from sweet potato is split into glucose, creating a sweet taste. The amino acids glutamic acid and to a lesser extent also aspartic acid split off from the proteins during fermentation, resulting in a strong umami taste. Depending on the Aspergillus used, culture substrate and culture conditions (temperature, pH value, salt content, humidity), different products are created in terms of composition, flavour and odour. Kōji can be freeze-dried and crushed to produce spores. Dried kōji-spores can be stored and transported light-protected at room temperature.
== Origins == In 1927, Sakel, who had recently qualified as a medical doctor in Vienna and was working in a psychiatric clinic in Berlin, began to use low (sub-coma) doses of insulin to treat drug addicts and psychotics, and when one of the patients experienced improved mental clarity after having slipped into an accidental coma, Sakel reasoned the treatment might work for mentally ill patients. Having returned to Vienna, he treated schizophrenic patients with larger doses of insulin in order to deliberately produce coma and sometimes convulsions. Sakel made his results public in 1933, and his methods were soon taken up by other psychiatrists. Joseph Wortis, after seeing Sakel practice it in 1935, introduced it to the US. British psychiatrists from the Board of Control visited Vienna in 1935 and 1936, and by 1938, 31 hospitals in England and Wales had insulin treatment units. In 1936, Sakel moved to New York and promoted the use of insulin coma treatment in US psychiatric hospitals. By the late 1940s, the majority of psychiatric hospitals in the US were using insulin coma treatment.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.